Treatment of central sensitization in patients with 'unexplained' chronic pain: what options do we have?
Nijs, Jo, Meeus, Mira, Van Oosterwijck, Jessica et al. · Expert opinion on pharmacotherapy · 2011 · DOI
Quick Summary
This review examines how the nervous system can become overly sensitive to pain signals, a condition called central sensitization that occurs in many chronic pain disorders including ME/CFS. The authors summarize different treatment approaches—including medications, physical therapy, brain stimulation, and stress management—that may help calm down an overactive pain processing system in the brain and spinal cord.
Why It Matters
Central sensitization is increasingly recognized as a key mechanism in ME/CFS pathology, and this review comprehensively maps available treatment options targeting this mechanism. For ME/CFS patients, understanding multiple potential approaches—from medications to rehabilitation to neuromodulation—may help identify personalized treatment strategies. This work validates central sensitization as a legitimate treatment target in ME/CFS alongside other post-viral and immunological mechanisms.
Observed Findings
Central sensitization occurs across multiple chronic pain disorders including chronic fatigue syndrome, fibromyalgia, chronic low back pain, and temporomandibular disorders.
Multiple drug classes (SSRIs, SNRIs, NMDA antagonists, calcium-channel ligands) target neurotransmitter and receptor systems involved in central pain processing.
Non-pharmacological approaches including manual therapy, stress management, TENS, and transcranial magnetic stimulation can theoretically desensitize the central nervous system.
Combining multiple treatment modalities targeting central sensitization is advocated rather than single-intervention approaches.
Inferred Conclusions
Central sensitization should be explicitly recognized and targeted as a treatment goal in patients with unexplained chronic pain disorders including ME/CFS.
Multiple evidence-based interventions exist that target different mechanisms of central sensitization and may be combined for comprehensive treatment.
Integrated treatment combining pharmacological, rehabilitative, and neuromodulatory approaches is likely superior to single-modality treatment.
Clinicians should match specific interventions to the pathophysiological mechanisms of central sensitization operating in individual patients.
Remaining Questions
Which combinations of treatments targeting central sensitization produce optimal outcomes in ME/CFS specifically?
What This Study Does Not Prove
This narrative review does not provide definitive evidence that any single treatment is effective for ME/CFS specifically—it summarizes theoretical mechanisms and evidence from other central sensitization conditions. The review does not establish which approaches are most effective for ME/CFS patients in particular, nor does it quantify the magnitude of benefit across disorders. It does not address whether treatments targeting central sensitization alone are sufficient or must be combined with other ME/CFS-specific approaches.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How do the mechanisms of central sensitization in ME/CFS differ from other central sensitization disorders, and do these differences require different treatment priorities?
What is the relative effectiveness of pharmacological versus non-pharmacological approaches for central sensitization in ME/CFS?
How should central sensitization treatment be sequenced and integrated with other ME/CFS-specific interventions addressing post-viral immune dysfunction?